CBD-Intel

Asia

This page holds all of our content that relates to Asia and its many markets. This includes all of our news coverage (both business and regulatory), our databases and trackers, and our full-length regulatory and market reports.

Asian markets for CBD face individual regulatory and business challenges, with both legal frameworks and market conditions impacting individual CBD companies. We report on policy, law, market development and market analysis for Asia.

Featured topic

The Food and Drug Administration (FDA) rejected applications to use hemp extract as a dietary supplement.

Here are the conclusions we have attracted. CBD-Intel will continue to work on providing answers to the various questions that have arisen.

Blog | Policy and politics | US federal regulation

Sign up to our newsletter

By signing up you agree to our Terms and Conditions